(Q38927526)

7 September 2017

1 reference

title

Current status on prevention and treatment of canine leishmaniasis (English)

1 reference

7 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Carlos Garcia-Estrada

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Rafael Balaña-Fouce

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

author name string

Miguel Morán

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

Yolanda Pérez-Pertejo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

publication date

12 July 2016

1 reference

7 September 2017

Veterinary Parasitology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

volume

227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

page(s)

98-114

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

Canine Leishmania infantum enzymatic polymorphism: a review including 1023 strains of the Mediterranean area, with special reference to Algeria.

12 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmanicidal activity in vitro of Musa paradisiaca L. and Spondias mombin L. fractions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Identification of the agent causing visceral leishmaniasis in Uzbeki and Tajiki foci by analysing parasite DNA extracted from patients' Giemsa-stained tissue preparations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Genetic diversity of Leishmania donovani/infantum complex in China through microsatellite analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Safety and efficacy of antimicrobial peptides against naturally acquired leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Control of phlebotomine sandflies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Despite Leishvaccine and Leishmune trigger distinct immune profiles, their ability to activate phagocytes and CD8+ T-cells support their high-quality immunogenic potential against canine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Molecular mechanisms of antimony resistance in Leishmania

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Pancreatitis associated with N-methyl-glucamine therapy in a dog with leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A cross-sectional sero-epidemiological study of canine leishmaniasis in Greek mainland.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The pharmacology of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Indotecan (LMP400) and AM13-55: two novel indenoisoquinolines show potential for treating visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniasis: a diagnostic and clinical challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Chemotherapy of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Tick-borne infections of animals and humans: a common ground

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Cytokine gene expression in the tissues of dogs infected by Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domperidone: a peripherally acting dopamine2-receptor antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Immunological adjuvants. Determinant factors in the efficacy-toxicity ratio of the contemporary vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Disposition of antimony and aminosidine in dogs after administration separately and together: implications for therapy of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Disposition of Antimony and Aminosidine Combination After Multiple Subcutaneous Injections in Dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Miltefosine to treat leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The diagnosis and management of a case of leishmaniosis in a dog imported to Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The efficacy of enrofloxacin, alone or combined with metronidazole, in the therapy of canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Transplacental transmission of Leishmania infantum as a means for continued disease incidence in North America.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccination with LiESP/QA-21 (CaniLeish®) reduces the intensity of infection in Phlebotomus perniciosus fed on Leishmania infantum infected dogs--a preliminary xenodiagnosis study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Synthetic sex pheromone attracts the leishmaniasis vector Lutzomyia longipalpis (Diptera: Psychodidae) to traps in the field

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of a slow-release imidacloprid (10%)/flumethrin (4.5%) collar for the prevention of canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Effects of cationic diamidines on polyamine content and uptake on Leishmania infantum in in vitro cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Cytokine profiles in canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Clinical, serologic, and parasitologic follow-up after long-term allopurinol therapy of dogs naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Drug resistance in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A retrospective clinical study of canine leishmaniasis in 150 dogs naturally infected by Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of low doses of amphotericin B plus allicin against experimental visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A long-lasting topical deltamethrin treatment to protect dogs against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmaniasis chemotherapy--challenges and opportunities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Drug resistance in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Factors associated with the seroprevalence of leishmaniasis in dogs living around Atlantic Forest fragments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine visceral leishmaniasis: seroprevalence and risk factors in Cuiabá, Mato Grosso, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Diminished CD4+/CD25+ T cell and increased IFN-gamma levels occur in dogs vaccinated with Leishmune in an endemic area for visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antidermatophytic and antileishmanial activities of essential oils from Lippia gracilis Schauer genotypes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Thymol and eugenol derivatives as potential antileishmanial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A case of autochthonous canine leishmaniasis in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Gentamicin-attenuated Leishmania infantum vaccine: protection of dogs against canine visceral leishmaniosis in endemic area of southeast of Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Dogs vaccinated with gentamicin-attenuatedLeishmania infantumor infected with wild-type parasite can be distinguished by Western blotting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniosis in the Old and New Worlds: unveiled similarities and differences.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Deltamethrin and permethrin residue on long-lasting insecticidal nets after 18 months of use in a visceral leishmaniasis-endemic area in Nepal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Risk factors in the spread of leishmaniases: towards integrated monitoring?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Comparison of two commercial vaccines against visceral leishmaniasis in dogs from endemic areas: IgG, and subclasses, parasitism, and parasite transmission by xenodiagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evaluation of 65% permethrin spot-on and deltamethrin-impregnated collars for canine Leishmania infantum infection prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Deltamethrin-impregnated collars for the control of canine leishmaniasis: evaluation of the protective effect and influence on the clinical outcome of Leishmania infection in kennelled stray dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Pentavalent antimonials: new perspectives for old drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of dinotefuran, permethrin and pyriproxyfen combination spot-on against Aedes aegypti mosquitoes on dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of a new combination of fipronil and permethrin (Effitix®) against Phlebotomus perniciosus in dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Metronidazole. A therapeutic review and update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Update on the diagnosis and management of Leishmania spp infections in dogs in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Transmission of Leishmania infantum via blood transfusion in dogs: potential for infection and importance of clinical factors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Use of the nitroblue tetrazolium reduction test for the evaluation of Domperidone effects on the neutrophilic function of healthy dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Pentostam (sodium stibogluconate); a 50-year personal reminiscence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine Leishmania vaccines: still a long way to go.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The current status of zoonotic leishmaniases and approaches to disease control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Recent advances in leishmaniosis in pet animals: epidemiology, diagnostics and anti-vectorial prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The effect of removing potentially infectious dogs on the numbers of canine Leishmania infantum infections in an endemic area with high transmission rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Clinical and parasitological protection in a Leishmania infantum-macaque model vaccinated with adenovirus and the recombinant A2 antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domperidone and lactation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Neglected tropical diseases in sub-saharan Africa: review of their prevalence, distribution, and disease burden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Azaterphenyl diamidines as antileishmanial agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

In vivo dermal absorption of pyrethroid pesticides in the rat.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antileishmanial activity of two gamma-pyrones from Podolepsis hieracioides (Asteraceae).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Protection of dogs from bites of phlebotomine sandflies by deltamethrin collars for control of canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Clinical considerations on canine visceral leishmaniasis in Greece: a retrospective study of 158 cases (1989-1996)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Comparative microsatellite typing of new world leishmania infantum reveals low heterogeneity among populations and its recent old world origin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Asymptomatic dogs are highly competent to transmit Leishmania (Leishmania) infantum chagasi to the natural vector.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: Double-blind randomised efficacy field trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Randomized, double-blind, placebo-controlled, multicenter trial of 6% miltefosine solution, a topical chemotherapy in cutaneous metastases from breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of dinotefuran, permethrin and pyriproxyfen combination spot-on on dogs against Phlebotomus perniciosus and Ctenocephalides canis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evaluation of the cardiac toxicity of N-methyl-glucamine antimoniate in dogs with naturally occurring leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Prolactin regulates antitumor immune response through induction of tumoricidal macrophages and release of IL-12

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Interferon-gamma (INF-gamma), IL4 expression levels and Leishmania DNA load as prognostic markers for monitoring response to treatment of leishmaniotic dogs with miltefosine and allopurinol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Temporal IgG subclasses response in dogs following vaccination against Leishmania with Leishmune®

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Guidelines for prevention of leishmaniasis in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of the liposome trifluralin in the treatment of experimental canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniasis in southeastern Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The protective immune response produced in dogs after primary vaccination with the LiESP/QA-21 vaccine (CaniLeish®) remains effective against an experimental challenge one year later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine visceral leishmaniasis in Rio de Janeiro, Brazil. Clinical, parasitological, therapeutical and epidemiological findings (1977-1983)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The frequency and distribution of canine leishmaniosis diagnosed by veterinary practitioners in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Effects of P-MAPA immunomodulator on Toll-like receptor 2, ROS, nitric oxide, MAPKp38 and IKK in PBMC and macrophages from dogs with visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Repellent efficacy of a combination containing imidacloprid and permethrin against sand flies (Phlebotomus papatasi) in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evaluation of the efficacy of a topically administered combination of imidacloprid and permethrin against Phlebotomus perniciosus in dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniosis--new concepts and insights on an expanding zoonosis: part two.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of 65% permethrin applied to dogs as a spot-on against Phlebotomus perniciosus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Attraction of phlebotomine sand flies to baited and non-baited horizontal surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Genomic and Molecular Characterization of Miltefosine Resistance in Leishmania infantum Strains with Either Natural or Acquired Resistance through Experimental Selection of Intracellular Amastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Use of a LiESP/QA-21 vaccine (CaniLeish) stimulates an appropriate Th1-dominated cell-mediated immune response in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Primary vaccination with the LiESP/QA-21 vaccine (CaniLeish) produces a cell-mediated immune response which is still present 1 year later

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Pharmacokinetics, toxicities, and efficacies of sodium stibogluconate formulations after intravenous administration in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Treatment of canine Old World visceral leishmaniasis: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

An update on the diagnosis and treatment of canine leishmaniosis caused by Leishmania infantum (syn. L. chagasi).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Activity of liposomal amphotericin B (AmBisome) in dogs naturally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A randomised, double-blind, controlled efficacy trial of the LiESP/QA-21 vaccine in naïve dogs exposed to two leishmania infantum transmission seasons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The prevention of canine leishmaniasis and its impact on public health

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of a combination of 10% imidacloprid/50% permethrin for the prevention of leishmaniasis in kennelled dogs in an endemic area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Prevention of endemic canine vector-borne diseases using imidacloprid 10% and permethrin 50% in young dogs: a longitudinal field study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Prevention of canine leishmaniosis in a hyper-endemic area using a combination of 10% imidacloprid/4.5% flumethrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmaniasis: drugs in the clinic, resistance and new developments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

One Health: the global challenge of epidemic and endemic leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune in Brazilian endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccines for leishmaniasis in the fore coming 25 years.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccines for canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Clinical treatment of cutaneous leishmaniasis in dogs with furazolidone and domperidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of the treatment of dogs with leishmaniosis with a combination of metronidazole and spiramycin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Variation of proteinuria in dogs with leishmaniasis treated with meglumine antimoniate and allopurinol: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Comparison of aminosidine (paromomycin) and sodium stibogluconate for treatment of canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccination with a preparation based on recombinant cysteine peptidases and canine IL-12 does not protect dogs from infection with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domperidone. A review of its use in diabetic gastropathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA and vaccinia recombinant vectors expressing LACK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Amphotericin B kills unicellular leishmanias by forming aqueous pores permeable to small cations and anions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Biology of phlebotomine sand flies as vectors of disease agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Development of a leishmaniasis vaccine: the importance of MPL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine leishmaniasis: novel strategies for control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Topical insecticide treatments to protect dogs from sand fly vectors of leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Analysis of immune responses in dogs with canine visceral leishmaniasis before, and after, drug treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

In vitro effect of Aloe vera, Coriandrum sativum and Ricinus communis fractions on Leishmania infantum and on murine monocytic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Domperidone and long QT syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Efficacy of different treatment regimens of marbofloxacin in canine visceral leishmaniosis: a pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

One-year clinical and parasitological follow-up of dogs treated with marbofloxacin for canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A single-centre, open-label, controlled, randomized clinical trial to assess the preventive efficacy of a domperidone-based treatment programme against clinical canine leishmaniasis in a high prevalence area

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Improvement in clinical signs and cellular immunity of dogs with visceral leishmaniasis using the immunomodulator P-MAPA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Periodic administration of allopurinol is not effective for the prevention of canine leishmaniosis (Leishmania infantum) in the endemic areas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Thyroid function in 36 dogs with leishmaniosis due to Leishmania infantum before and during treatment with allopurinol with or without meglumine antimonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Retracted: Evaluation of Live Recombinant Nonpathogenic Leishmania tarentolae Expressing Cysteine Proteinase and A2 Genes as a Candidate Vaccine against Experimental Canine Visceral Leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Novel Intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Activity of cycloartane-type triterpenes and sterols isolated from Musa paradisiaca fruit peel against Leishmania infantum chagasi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Development of miltefosine as an oral treatment for leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The effect of intravenous or subcutaneous administration of meglumine antimonate (Glucantime) in dogs with leishmaniasis. A randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine visceral leishmaniasis in Teresina, Brazil: Relationship between clinical features and infectivity for sand flies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Novel amidines and analogues as promising agents against intracellular parasites: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Prevalence of Leishmania infantum infection in dogs living in an area of canine leishmaniasis endemicity using PCR on several tissues and serology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Directions for the diagnosis, clinical staging, treatment and prevention of canine leishmaniosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Interleukin-12 augments a Th1-type immune response manifested as lymphocyte proliferation and interferon gamma production in Leishmania infantum-infected dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Risk of infection with Leishmania spp. in the canine population in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antibody responses induced by Leish-Tec®, an A2-based vaccine for visceral leishmaniasis, in a heterogeneous canine population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Humoral and in vivo cellular immunity against the raw insect-derived recombinant Leishmania infantum antigens KMPII, TRYP, LACK, and papLe22 in dogs from an endemic area.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Antimicrobial peptide action on parasites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Long term follow-up of dogs diagnosed with leishmaniosis (clinical stage II) and treated with meglumine antimoniate and allopurinol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Pharmacokinetics of meglumine antimoniate after administration of a multiple dose in dogs experimentally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Leishmania-macrophage interactions: insights into the redox biology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Possible mechanism of miltefosine-mediated death of Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Failure of buparvaquone (Butalex) in the treatment of canine visceral leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Visceral leishmaniasis: a One Health approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Dogs immunized with LBSap vaccine displayed high levels of IL-12 and IL-10 cytokines and CCL4, CCL5 and CXCL8 chemokines in the dermis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Canine visceral leishmaniasis: comparison of in vitro leishmanicidal activity of marbofloxacin, meglumine antimoniate and sodium stibogluconate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

The prevalence of canine Leishmania infantum infection in western China detected by PCR and serological tests

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Effectiveness of insecticide spraying and culling of dogs on the incidence of Leishmania infantum infection in humans: a cluster randomized trial in Teresina, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Clinical efficacy and tolerance of miltefosine in the treatment of canine leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

A systematic review of the efficacy of prophylactic control measures for naturally occurring canine leishmaniosis. Part II: topically applied insecticide treatments and prophylactic medications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Prospective evaluation of serum pancreatic lipase immunoreactivity and troponin I concentrations in Leishmania infantum-infected dogs treated with meglumine antimonate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Allopurinol Resistance in Leishmania infantum from Dogs with Disease Relapse

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Clinical recovery and limited cure in canine visceral leishmaniasis treated with aminosidine (paromomycin).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETPAR.2016.07.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VETPAR.2016.07.011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27523945%20AND%20SRC:MED&resulttype=core&format=json

12 June 2020

1 reference